

ASTRO School of Radiation Oncology

MOC Online Self-assessment Module

Biosketch Information

Christopher H. Crane, M.D.

Associate Professor, Program Director and Chief, Gastrointestinal Section, Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston

Brief Disclosure Statement

Research funding from Bristol Meyer Squibb. Honoraria from Roche and Sanofi-Aventis.

Brief Description of Responsibilities:

Dr Christopher Crane serves as the program director of the gastrointestinal section at the University of Texas. He is involved in the clinical care of patients with gastrointestinal malignancies. He also services as the program director of the Residency and Fellowship Training Program

Educational Preparation: University of Miami, Coral Gables, Fla., B.S., 1989, Biology; University of Virginia, Charlottesville, Va., M.D, 1993, Medicine

Internship: Transitional Internship, Roanoke Memorial Hospital, Roanoke, Va., 1993-1994

Residency: Resident, Radiation Oncology, The University of Virginia, Charlottesville, Va., 1994-1998; Chief Resident (2 Years), Radiation Oncology, The University of Virginia, Charlottesville, Va., 1996-1998

Degree: M.D.

Major Area of Study: Medicine

Year Earned: 1993

Select Papers:

1. Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. *Gastrointest Cancer Res* 2:1-14, 1/2008.
2. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S, Briere TM, Crane CH, Mornex F. Radiation therapy for hepatocellular carcinoma. *Ann Surg Oncol* 15(4):1015-1024, 4/2008.
3. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. *J Am Coll Surg* 206(5):833-846; discussion 846-848, 5/2008.
4. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. *Int J Radiat Oncol Biol Phys* 71(1):167-172, 5/2008.
5. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerke GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative Gemcitabine-based Chemoradiation for Patients with Resectable Adenocarcinoma of the Pancreatic Head. *J Clin Oncol* 26(21):3496-3502, 7/2008.
6. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. *Ann Surg Oncol* 15(11):3147-3156, 8/2008.
7. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerke GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. *J Clin Oncol* 26(21):3487-3495, 8/2008.
8. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. *Clin Colorectal Cancer* 7(5):338-42, 9/2008.
9. Wang X, Krishnan S, Zhang X, Dong L, Briere T, Crane CH, Martel M, Gillin M, Mohan R, Beddar S. Proton Radiotherapy for Liver Tumors: Dosimetric Advantages over Photon Plans. *Med Dosim* 33(4):259-67, 2008.